MXCT — MAXCYTE, INC.

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1287098 ·
Last close
$1.17
Market Cap
$120.80M
52W High
$1.80
52W Low
$0.64
ADV30
1,690,855
Next earnings
2026-11-10
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 10,152,000 8,468,000 -6,041,000 -4,762,000 182,483,000 13,372,000 31,552,000
Jun 2026 7,271,000 5,596,000 -10,232,000 -8,874,000 184,672,000 15,042,000 25,920,000
Mar 2026 9,651,000 8,082,000 -6,185,000 -4,750,000 194,473,000 14,557,000 26,587,000
Dec 2025 7,300,000 5,690,000 -7,672,000 -9,596,000 202,507,000 20,065,000 31,017,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-21,025,000
Investing CF
$26,756,000
Financing CF
$-5,332,000
CapEx
$-574,000
Dividends Paid
—
Buybacks
$-4,022,000
EPS Diluted TTM
$-0.26
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-279,869,000
Inventory
$7,380,000
Receivables
$12,054,000
ST Investments
$87,908,000
EBIT TTM
$-30,130,000
Pretax Income TTM
$-27,982,000
Interest Exp TTM
—
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$31,051,000
EBITDA
$-30,288,000
Free Cash Flow
$-13,138,125
Enterprise Value
$45,729,068
Total Cash
$105,690,000
Total Debt
$17,251,000
Shares Out
103,250,292
Trailing EPS
$-0.26
Book Value
$1.61
ROE
-20.4%
ROA
-10.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 33,026,000 -45,285,000 -44,630,000 202,507,000 31,017,000 171,490,000 -34,410,000
Dec 2024 38,627,000 -51,197,000 -41,055,000 239,470,000 33,219,000 206,251,000 -27,610,000
Dec 2023 41,288,000 -48,299,000 -37,923,000 268,274,000 36,107,000 232,167,000 -21,686,000
Dec 2022 44,261,000 -27,361,000 -23,571,000 286,653,000 32,685,000 253,968,000 -14,783,000

TTM Snapshot

Revenues TTM
$31,051,000
NetIncome TTM
$-35,636,000
OpCashFlow TTM
—
Assets (Latest)
$184,672,000
Forward EPS
$-0.23

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $1.25 · call volume: 20 · put volume: 50
Expected Move to 2027-04-16: ±$1.53 (122.00%) — implied range $-0.28 – $2.78 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ICCC IMMUCELL CORP /DE/ $103.01M $11.33 —
NNNN Anbio Biotechnology $160.20M $3.65 —
IMDX Insight Molecular Diagnostics Inc. $58.25M $1.78 —
IBAC IB Acquisition Corp. $54.33M $10.85 —
ONMD OneMedNet Corp $293.47M $4.95 —

News headlines (Yahoo Finance, 1h cache)

MaxCyte, Inc. Q3 2026 Earnings Call Summary
2026-11-11 13:30 · Yahoo
MaxCyte (MXCT) Q3 2026 Earnings Call Transcript
2026-11-11 05:15 · Yahoo
MaxCyte Inc (MXCT) (Q3 2026) Earnings Call Highlights: Revenue Surges 49% as Accron Acquisition ...
2026-11-11 05:09 · Yahoo
MaxCyte Q3 Earnings Call Highlights
2026-11-10 18:15 · Yahoo
MaxCyte to Acquire Akron Bio for $151.8 Million
2026-11-10 12:01 · Yahoo
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
2026-11-10 11:01 · Yahoo
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
2026-11-10 11:00 · Yahoo
MaxCyte to Participate in Three Upcoming Investor Conferences
2026-10-28 12:05 · Yahoo
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
2026-10-14 12:05 · Yahoo
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
2026-09-23 12:05 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-11-18 16:38:12 2026-11-17 Masoud Maher Pres, CEO P - Purchase 1.21 100000 120780